Nucleai, a spatial AI biomarker startup based in Chicago, IL and Tel Aviv, Israel, raised $14M in funding.

M Ventures led the round, with existing investors also participating. The funds will be used to accelerate the deployment of Nucleai's spatial analysis technology.

Led by CEO Avi Veidman, Nucleai leverages geospatial analytical methods to analyze tissue samples, aiding in the development of bi-specifics, antibody-drug conjugates (ADCs), and immunotherapy. The platform provides pathologists and researchers with actionable insights.

The company aims to drive innovation at the intersection of technology and healthcare, enhancing its market position with the new investment.